Literature DB >> 25131238

Regulation of lovastatin on a key inflammation-related microRNA in myocardial cells.

Weizao Guo1, Huichen Liu2, Lin Li3, Man Yang2, Aihua Du2.   

Abstract

BACKGROUND: Advances in the understanding of cardiovascular pathogenesis have highlighted that inflammation plays a central role in atherosclerotic coronary heart disease. Therefore, exploring pharmacologically based anti-inflammatory treatments to be used in cardiovascular therapeutics is worthwhile to promote the discovery of novel ways of treating cardiovascular disorders.
METHODS: The myocardial cell line H9c2(2-1) was exposed to lipopolysaccharide (LPS) in culture and resulted in a cellular pro-inflammation status. miR-21 microRNA levels were detected using quantitative real-time polymerase chain reaction (Q-RT-PCR). The influence of lovastatin on miR-21 under normal and pro-inflammatory conditions was tested after being added to the cell culture mixture for 24 hours. Conditional gene function of two predicted cardiovascular system relevant downstream targets of miR-21, protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and signal transducer and activator of transcription 3 (STAT3), were analyzed with immunoblotting.
RESULTS: Forty-eight hours of LPS treatment significantly increased the miR-21 to 170.71%± 34.32% of control levels (P = 0.002). Co-treatment with lovastatin for 24 hours before harvesting attenuated the up-regulation of miR-21 (P = 0.013). Twenty-four hours of lovastatin exposure up-regulated PPP1R3A to 143.85%± 21.89% of control levels in cardiomyocytes (P = 0.023). Lovastatin up-regulated the phosphorylation level of STAT3 compared to the background LPS pretreatment (P = 0.0077), this effect was significantly (P = 0.018) blunted when miR-21 was functionally inhibited.
CONCLUSIONS: miR-21 plays a major role in the regulation of the cellular anti-inflammation effects of lovastatin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131238

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

1.  Association of Leu125Val polymorphisms in the PECAM-1 gene with the risk of coronary heartdisease: a meta-analysis.

Authors:  Tao Xia; Xin Liu; Chang Jiang Du; Xin Jin; Xiang Qian Kong; Gang Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Association Between Coronary Artery Disease and MicroRNA: Literature Review and Clinical Perspective.

Authors:  Rehan Malik; Raja S Mushtaque; Usman A Siddiqui; Adnan Younus; Muhammad A Aziz; Choudhry Humayun; Kanaan Mansoor; Muhammad A Latif; Salman Waheed; Salman Assad; Idrees Khan; Syed M Bukhari; Daniel DelCampo; Ali Adus; Swetha Gannarapu
Journal:  Cureus       Date:  2017-04-23

Review 3.  Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.

Authors:  Elena Arrigoni; Marzia Del Re; Leonardo Fidilio; Stefano Fogli; Romano Danesi; Antonello Di Paolo
Journal:  Int J Mol Sci       Date:  2017-01-06       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.